These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29664840)

  • 21. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
    Hamilton CA; Maxwell GL; Chernofsky MR; Bernstein SA; Farley JH; Rose GS
    Gynecol Oncol; 2008 Dec; 111(3):530-2. PubMed ID: 18561992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients.
    Riedel AN; Kimer N; Jensen AH; Dahl EK; Israelsen M; Aamann L; Gluud LL
    World J Gastroenterol; 2018 Apr; 24(15):1650-1657. PubMed ID: 29686472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma.
    Hirte HW; Miller D; Tonkin K; Findlay B; Capstick V; Murphy J; Buckman R; Carmichael J; Levine M; Hill W
    Gynecol Oncol; 1997 Jan; 64(1):80-7. PubMed ID: 8995552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life improves after palliative placement of percutaneous tunneled drainage catheter for refractory ascites in prospective study of patients with end-stage cancer.
    Robson PC; Gonen M; Ni A; Brody L; Brown KT; Getrajdman G; Thom B; Kline N; Covey A
    Palliat Support Care; 2019 Dec; 17(6):677-685. PubMed ID: 30880658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis.
    Seike M; Maetani I; Sakai Y
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2161-6. PubMed ID: 18031375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
    Gotlieb WH; Amant F; Advani S; Goswami C; Hirte H; Provencher D; Somani N; Yamada SD; Tamby JF; Vergote I
    Lancet Oncol; 2012 Feb; 13(2):154-62. PubMed ID: 22192729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.
    Colombo N; Mangili G; Mammoliti S; Kalling M; Tholander B; Sternas L; Buzenet G; Chamberlain D
    Gynecol Oncol; 2012 Apr; 125(1):42-7. PubMed ID: 22112608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
    Burges A; Wimberger P; Kümper C; Gorbounova V; Sommer H; Schmalfeldt B; Pfisterer J; Lichinitser M; Makhson A; Moiseyenko V; Lahr A; Schulze E; Jäger M; Ströhlein MA; Heiss MM; Gottwald T; Lindhofer H; Kimmig R
    Clin Cancer Res; 2007 Jul; 13(13):3899-905. PubMed ID: 17606723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EUS-guided paracentesis for the diagnosis of malignant ascites.
    Kaushik N; Khalid A; Brody D; McGrath K
    Gastrointest Endosc; 2006 Dec; 64(6):908-13. PubMed ID: 17140897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sonographically guided paracentesis for palliation of symptomatic malignant ascites.
    Ross GJ; Kessler HB; Clair MR; Gatenby RA; Hartz WH; Ross LV
    AJR Am J Roentgenol; 1989 Dec; 153(6):1309-11. PubMed ID: 2479242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient experience of non-malignant ascites and its treatment: a qualitative study.
    Day R; Hollywood C; Durrant D; Perkins P
    Int J Palliat Nurs; 2015 Aug; 21(8):372-9. PubMed ID: 26312532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Malignant ascites: systematic review and guideline for treatment.
    Becker G; Galandi D; Blum HE
    Eur J Cancer; 2006 Mar; 42(5):589-97. PubMed ID: 16434188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MELD score and albumin replacement are related to higher costs during management of patients with refractory ascites.
    Borges de Santana V; Bertocco de Paiva Haddad L; Morgado Conte T; Cortez Rizzon A; Miranda Barbosa V; Shield W; Andraus W; Augusto Carneiro D'Albuquerque L
    Transplant Proc; 2014; 46(6):1760-3. PubMed ID: 25131030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current and future options in the treatment of malignant ascites in ovarian cancer.
    Woopen H; Sehouli J
    Anticancer Res; 2009 Aug; 29(8):3353-9. PubMed ID: 19661355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites.
    Mackey JR; Wood L; Nabholtz J; Jensen J; Venner P
    J Pain Symptom Manage; 2000 Mar; 19(3):193-9. PubMed ID: 10760624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, complications and outcome of large volume paracentesis with or without albumin therapy in children with severe ascites due to liver disease.
    Sen Sarma M; Yachha SK; Bhatia V; Srivastava A; Poddar U
    J Hepatol; 2015 Nov; 63(5):1126-32. PubMed ID: 26134185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter.
    Iyengar TD; Herzog TJ
    Am J Hosp Palliat Care; 2002; 19(1):35-8. PubMed ID: 12171424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
    Heiss MM; Murawa P; Koralewski P; Kutarska E; Kolesnik OO; Ivanchenko VV; Dudnichenko AS; Aleknaviciene B; Razbadauskas A; Gore M; Ganea-Motan E; Ciuleanu T; Wimberger P; Schmittel A; Schmalfeldt B; Burges A; Bokemeyer C; Lindhofer H; Lahr A; Parsons SL
    Int J Cancer; 2010 Nov; 127(9):2209-21. PubMed ID: 20473913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Methods of symptom control in malignant ascites].
    Bodisch A; Muschitz C; Karthaus M
    Wien Med Wochenschr; 2008; 158(23-24):687-94. PubMed ID: 19165448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.